Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo

被引:18
作者
Ofer, Philipp [1 ]
Heidegger, Isabel [1 ]
Eder, Iris E. [1 ]
Schoepf, Bernd [2 ]
Neuwirt, Hannes [3 ]
Geley, Stephan [4 ]
Klocker, Helmut [1 ]
Massoner, Petra [1 ]
机构
[1] Med Univ Innsbruck, Div Expt Urol, Dept Urol, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, A-6020 Innsbruck, Austria
[3] Med Univ Innsbruck, Dept Internal Med 4, A-6020 Innsbruck, Austria
[4] Med Univ Innsbruck, Div Mol Pathophysiol, Bioctr, A-6020 Innsbruck, Austria
基金
奥地利科学基金会;
关键词
GROWTH-FACTOR I; PHASE-II; SURVIVIN EXPRESSION; INSULIN; BCL-2; CELLS; PROLIFERATION; FIGITUMUMAB; AUTOPHAGY; DIFFERENTIATION;
D O I
10.1210/me.2015-1073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The IGF network with its main receptors IGF receptor 1 (IGF1R) and insulin receptor (INSR) is of major importance for cancer initiation and progression. To date, clinical studies targeting this network were disappointing and call for thorough analysis of the IGF network in cancer models. We highlight the oncogenic effects controlled by IGF1R and INSR in prostate cancer cells and show similarities as well as differences after receptor knockdown (KD). In PC3 prostate cancer cells stably transduced with inducible short hairpin RNAs, targeting IGF1R or INSR attenuated cell growth and proliferation ultimately driving cells into apoptosis. IGF1R KD triggered rapid and strong antiproliferative and proapoptotic responses, whereas these effects were less pronounced and delayed after INSR KD. Down-regulation of the antiapoptotic proteins myeloid cell leukemia-1 and survivin was observed in both KDs, whereas IGF1R KD also attenuated expression of prosurvival proteins B cell lymphoma-2 and B cell lymphoma-xL. Receptor KD induced cell death involved autophagy in particular upon IGF1R KD; however, no difference in mitochondrial energy metabolism was observed. In a mouse xenograft model, induction of IGF1R or INSR KD after tumor establishment eradicated most of the tumors. After 20 days of receptor KD, tumor cells were found only in 1/14 IGF1R and 3/14 INSR KD tumor remnants. Collectively, our data underline the oncogenic functions of IGF1R and INSR in prostate cancer namely growth, proliferation, and survival in vitro as well as in vivo and identify myeloid cell leukemia-1 and survivin as important mediators of inhibitory and apoptotic effects.
引用
收藏
页码:1694 / 1707
页数:14
相关论文
共 51 条
  • [1] A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
    Abulwerdi, Fardokht
    Liao, Chenzhong
    Liu, Meilan
    Azmi, Asfar S.
    Aboukameel, Amro
    Mady, Ahmed S. A.
    Gulappa, Thippeswamy
    Cierpicki, Tomasz
    Owens, Scott
    Zhang, Tao
    Sun, Duxin
    Stuckey, Jeanne A.
    Mohammad, Ramzi M.
    Nikolovska-Coleska, Zaneta
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (03) : 565 - 575
  • [2] Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma
    Adisetiyo, Helty
    Liang, Mengmeng
    Liao, Chun-Peng
    Aycock-Williams, Ari
    Cohen, Michael B.
    Xu, Shili
    Neamati, Nouri
    Conway, Edward M.
    Cheng, Chieh-Yang
    Nikitin, Alexander Yu.
    Roy-Burman, Pradip
    [J]. PLOS ONE, 2013, 8 (07):
  • [3] Inflammation and cancer: How hot is the link?
    Aggarwal, Bharat B.
    Shishodia, Shishir
    Sandur, Santosh K.
    Pandey, Manoj K.
    Sethi, Gautam
    [J]. BIOCHEMICAL PHARMACOLOGY, 2006, 72 (11) : 1605 - 1621
  • [4] Targeting survivin in cancer
    Altieri, Dario C.
    [J]. CANCER LETTERS, 2013, 332 (02) : 225 - 228
  • [5] Metabolic Stress in Autophagy and Cell Death Pathways
    Altman, Brian J.
    Rathmell, Jeffrey C.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2012, 4 (09):
  • [6] The IGF-I receptor in cell growth, transformation and apoptosis
    Baserga, R
    Hongo, A
    Rubini, M
    Prisco, M
    Valentinis, B
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1332 (03): : F105 - F126
  • [7] Chen H, 1998, CELL GROWTH DIFFER, V9, P939
  • [8] A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer
    Chi, Kim N.
    Gleave, Martin E.
    Fazli, Ladan
    Goldenberg, S. Larry
    So, Alan
    Kollmannsberger, Christian
    Murray, Nevin
    Tinker, Anna
    Pollak, Michael
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3407 - 3413
  • [9] Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
    de Bono, Johann S.
    Piulats, Josep M.
    Pandha, Hardev S.
    Petrylak, Daniel P.
    Saad, Fred
    Aparicio, Luis Miguel A.
    Sandhu, Shahneen K.
    Fong, Peter
    Gillessen, Silke
    Hudes, Gary R.
    Wang, Tao
    Scranton, Judith
    Pollak, Michael N.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1925 - 1934
  • [10] Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055
    Dueregger, Andrea
    Guggenberger, Fabian
    Barthelmes, Jan
    Stecher, Guenther
    Schuh, Markus
    Intelmann, Daniel
    Abel, Gudrun
    Haunschild, Jutta
    Klocker, Helmut
    Ramoner, Reinhold
    Sampson, Natalie
    [J]. PHYTOMEDICINE, 2013, 20 (14) : 1306 - 1314